Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles  Tsung-Hsien.

Slides:



Advertisements
Similar presentations
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Advertisements

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.
A giant oocyte in a cohort of retrieved oocytes: does it have any effect on the in vitro fertilization cycle outcome?  Ronit Machtinger, M.D., Joseph.
Genome-based expression profiling as a single standardized microarray platform for the diagnosis of endometrial disorder: an array of 126-gene model 
Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.
The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
Fernando Zegers-Hochschild, M.D.  Fertility and Sterility 
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
Michael M. Alper, M.D.  Fertility and Sterility 
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Zhi-Yong Yang, M.D., Ri-Cheng Chian, Ph.D.  Fertility and Sterility 
Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist.
The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.
A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women 
Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study  Nicole Hope, M.B., B.S., Hon., Luk.
Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy  Ewa Nowak-Markwitz,
Effect of the oxytocin antagonist antocin and agonist decomoton on baboon luteal cell production and release of progesterone  M. Yusoff Dawood, M.D.,
Medical treatment of ectopic pregnancy: a committee opinion
The relative contribution of assisted reproductive technologies and ovulation induction to multiple births in the United States 5 years after the Society.
Failure of the GnRH antagonist ganirelix to block the positive feedback effect of exogenous estrogen in normal women  Ioannis E. Messinis, M.D., Ph.D.,
Modified natural cycle in in vitro fertilization
Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D. 
Impact of submucous myoma on the severity of anemia
Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization  Ginny Mounce,
Increased matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 secretion but unaffected invasiveness of endometrial stromal cells in.
Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.
Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted.
Martin D. Keltz, M. D. , Josh C. Skorupski, M. D. , Katrina Bradley, M
Oocyte cryopreservation
Genome-based expression profiling as a single standardized microarray platform for the diagnosis of endometrial disorder: an array of 126-gene model 
Robert F. Casper, M.D.  Fertility and Sterility 
Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration 
Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic.
Clomiphene citrate at 50: the dawning of assisted reproduction
Insulin-like growth factor-II (IGF-II), IGF-binding protein-3 (IGFBP-3), and IGFBP-4 in follicular fluid are associated with oocyte maturation and embryo.
Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles  Karin.
Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.
Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection  Dorothea M.
Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting  Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.
Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol  Georg Griesinger, M.D., Anja Dawson, M.D., Askan Schultze-Mosgau,
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series  Nanette L. Rollene,
Markedly elevated plasma myeloperoxidase protein in patients with pelvic inflammatory disease who have A allele myeloperoxidase gene polymorphism  Shun-An.
Effectiveness of highly purified human menopausal gonadotropin vs
Are endometrial parameters by three-dimensional ultrasound and power Doppler angiography related to in vitro fertilization/embryo transfer outcome?  Luis.
Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men  Subodhsingh Chauhan, M.D.,
The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is.
Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization  David W. Schmidt, M.D.,,
Fertility and Sterility: an evaluation
Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins:
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.
Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization  Efstratios M Kolibianakis, M.D., Kostas.
Office hysteroscopic early lysis of intrauterine adhesion after transcervical resection of multiple apposing submucous myomas  Jehn-Hsiahn Yang, M.D.,
David H. Barad, M.D., M.S., Norbert Gleicher, M.D. 
Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists 
In vitro sildenafil citrate use as a sperm motility stimulant
Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian.
Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles 
Progesterone level and progesterone/estradiol ratio on the day of hCG administration: detrimental cutoff levels and new treatment strategy  Eman A. Elgindy,
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.
Randomized, controlled pilot trial of natural versus hormone replacement therapy cycles in frozen embryo replacement in vitro fertilization  Ginny Mounce,
Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.
In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation 
P-24 Fertility and Sterility Volume 85, Pages S19-S20 (April 2006)
Logarithmic curves depicting initial level and rise of serum beta human chorionic gonadotropin and live delivery outcomes with in vitro fertilization:
Presentation transcript:

Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles  Tsung-Hsien Lee, M.D., Ming-Yih Wu, M.D., Hsin-Fu Chen, M.D., Shee-Uan Chen, M.D., Hong-Nerng Ho, M.D., Yu-Shih Yang, M.D., Ph.D.  Fertility and Sterility  Volume 86, Issue 4, Pages 1020-1022 (October 2006) DOI: 10.1016/j.fertnstert.2006.02.121 Copyright © 2006 American Society for Reproductive Medicine Terms and Conditions

FIGURE 1 The levels of serum NO of the two studied groups on the first (DH1) and second (DH2) day after administration of hCG were significantly different (P=.033 and P=.030, respectively). The cumulative embryo scores for the best three embryos (Top3) showed significant difference (P=.032) (Wilcoxon signed rank test). Lee. Nitric oxide after GnRH antagonist. Fertil Steril 2006. Fertility and Sterility 2006 86, 1020-1022DOI: (10.1016/j.fertnstert.2006.02.121) Copyright © 2006 American Society for Reproductive Medicine Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.